NASDAQ · TRVI
Trevi Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TRVI: Nov 12, 2026
Trevi Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.13. The reported EPS for the same quarter last year was $-0.08.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.13 | $-0.11 | $-0.15 | 6 |
| Dec 2026 | $-0.14 | $-0.12 | $-0.18 | 6 |
| Mar 2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
NASDAQ.com · MarketBeat · RTTNews · BNK Invest- NASDAQ.com · Oct 12, 4:24 PM EDTAfter Hours Most Active for Oct 12, 2026 : NU, CMCSA, INDV, CTRI, NVDA, SNAP, TRVI, TJX, GOOGL, AMZN, CBZ, NOKThe NASDAQ 100 After Hours Indicator is down -10.15 to 30,654.55. The total After hours volume is currently 121,212,545 shares traded.The following are the most active stocks for the after hours session: Nu Holdings Ltd. (NU) is -0.03 at $15.98, with 7,305,742 shares traded. NU'
- NASDAQ.com · Oct 9, 4:24 PM EDTAfter Hours Most Active for Oct 9, 2026 : FTXR, NVDA, BKD, GRAB, TRVI, URGN, INDV, LUV, WFC, ESI, OSG, BACThe NASDAQ 100 After Hours Indicator is down -5.38 to 30,877.77. The total After hours volume is currently 134,392,844 shares traded.The following are the most active stocks for the after hours session: First Trust Nasdaq Transportation ETF (FTXR) is unchanged at $41.53, with 18
- MarketBeat · Aug 7, 2:04 PM EDTTrevi Therapeutics Q2 Earnings Call HighlightsMarketBeat’s Top 5 Rated Small-Cap StocksTrevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications
- RTTNews · Jul 23, 6:50 AM EDTSerina Appoints Simon To Board; Concludes Dosing In Phase 1b For Parkinson's Therapy SER-252(RTTNews) – Serina Therapeutics, Inc. (SER), a biotechnology company, on Wednesday announced the appointment of Farrell Simon to the Board of Directors, effective immediately.
- BNK Invest · Jul 7, 12:55 PM EDTTuesday's ETF Movers: IHE, PSIIn trading on Tuesday, the iShares US Pharmaceuticals ETF is outperforming other ETFs, up about 3.1% on the day. Components of that ETF showing particular strength include shares of Crinetics Pharmaceuticals, up about 98.8% and shares of Trevi Therapeutics, up about 10.6% on th
- RTTNews · Jun 20, 6:13 AM EDT5 Biotech Stocks That Delivered Triple-Digit Gains – SYRE Up 400%, BFLY Up 300% & More(RTTNews) – As renowned American investor Peter Lynch once said, "Know what you own, and know why you own it." This timeless principle remains one of the cornerstones of successful investing.
- BNK Invest · Jun 18, 3:20 PM EDTNoteworthy Thursday Option Activity: TRVI, NTGR, ACMRLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Trevi Therapeutics Inc (Symbol: TRVI), where a total volume of 15,120 contracts has been traded thus far today, a contract volume which is representative of appr
- The Motley Fool · Jun 3, 10:04 AM EDTTrevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.Added 296,944 shares of Trevi Therapeutics; estimated buy value ~$3.32 million based on quarterly average price.
- MarketBeat · May 9, 5:05 AM EDTTrevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030MarketBeat’s Top 5 Rated Small-Cap StocksTrevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commerci
- RTTNews · May 6, 6:08 AM EDTTrevi Reports Q1 Results, To Begin Phase 3 Trial Of Haduvio In IPF-related Chronic Cough In Q2(RTTNews) – Trevi Therapeutics Inc. (TRVI), a clinical-stage biopharmaceutical company, announced on Tuesday its first-quarter financial results and provided updates on advancing Haduvio for the treatment of various chronic cough indications.
- RTTNews · Apr 17, 5:08 AM EDTTrevi Hits 52-Week High After Public Offering Pricing(RTTNews) – Trevi Therapeutics Inc. (TRVI), a clinical-stage biopharmaceutical company, announced on Thursday the pricing for an underwritten public offering of 11,600,000 shares of common stock at $13 per share.
- The Motley Fool · Mar 18, 9:39 AM EDTTrevi Therapeutics (TRVI) Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Trevi Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.